Format

Send to

Choose Destination
Cardiol Clin. 2019 Nov;37(4):533-544. doi: 10.1016/j.ccl.2019.07.002.

Cardiovascular Toxicities in Pediatric Cancer Survivors.

Author information

1
Department of Pediatrics, Division of Pediatric Cardiology, Heart Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, MLC 2003, Cincinnati, OH 45229, USA. Electronic address: thomas.ryan@cchmc.org.
2
Department of Pediatrics, Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, MLC 7018, Cincinnati, OH 45229, USA.
3
Department of Pediatrics, Division of Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, 2200 Children's Way, Suite 5230 DOT, Nashville, TN 37232, USA.

Abstract

Advances in cancer therapies have significantly improved patient outcomes. However, with improvements in survival, the toxicities associated with cancer therapy have become of paramount importance and oncologists are faced with the challenge of establishing therapeutic efficacy while minimizing toxicity. Cardiovascular disease represents a significant risk to survivors of childhood cancer and is a major cause of morbidity and mortality. This article outlines the current state of knowledge regarding cardiotoxicity in children undergoing cancer therapies, including the impact of specific oncologic therapies, recommendations for cardiovascular screening, the management of established cardiac disease, and the evolving field of pediatric cardio-oncology.

KEYWORDS:

Anthracycline; Cardio-oncology; Cardiomyopathy; Cardiotoxicity; Chemotherapy; Heart failure; Oncocardiology; Pediatric cardiology

PMID:
31587793
DOI:
10.1016/j.ccl.2019.07.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center